Long-term safety of childhood growth hormone treatment: evidences from real-world study and future directions.
作者信息
Zhang Cai, Liang Yan, Luo Xiao-Ping
机构信息
Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China.
Hubei Key Laboratory of Pediatric Genetic Metabolic and Endocrine Rare Diseases, Wuhan, China.
出版信息
World J Pediatr. 2025 Jan;21(1):3-7. doi: 10.1007/s12519-024-00862-7. Epub 2024 Dec 12.
Abstract
摘要
相似文献
1
Long-term safety of childhood growth hormone treatment: evidences from real-world study and future directions.儿童生长激素治疗的长期安全性：来自真实世界研究的证据及未来方向。
World J Pediatr. 2025 Jan;21(1):3-7. doi: 10.1007/s12519-024-00862-7. Epub 2024 Dec 12.
2
Childhood growth hormone treatment: challenges, opportunities, and considerations.儿童生长激素治疗：挑战、机遇与考量
Lancet Child Adolesc Health. 2024 Aug;8(8):600-610. doi: 10.1016/S2352-4642(24)00127-5. Epub 2024 Jun 27.
3
Long-Term Efficacy and Safety of Growth Hormone in Children Suffering from Short Stature in China (CGLS): An Open-Label, Multicenter, Prospective and Retrospective, Observational Study.生长激素在中国矮小儿童中的长期疗效和安全性（CGLS）：一项开放标签、多中心、前瞻性和回顾性观察性研究。
Adv Ther. 2025 Jun;42(6):2957-2969. doi: 10.1007/s12325-025-03146-2. Epub 2025 Apr 8.
4
Effect of long-acting PEGylated growth hormone for catch-up growth in children with idiopathic short stature: a 2-year real-world retrospective cohort study.长效聚乙二醇化人生长激素治疗特发性身材矮小儿童追赶生长的效果：一项 2 年真实世界回顾性队列研究。
Eur J Pediatr. 2024 Oct;183(10):4531-4539. doi: 10.1007/s00431-024-05719-9. Epub 2024 Aug 19.
5
Safety and Effectiveness of a Biosimilar Recombinant Growth Hormone in Adults with Growth Hormone Deficiency: Analysis of Final Data from PATRO Adults, an International Post-Marketing Surveillance Study.一种生物类似物重组生长激素在成年生长激素缺乏患者中的安全性和有效性：来自国际上市后监测研究PATRO Adults的最终数据分析
Drug Des Devel Ther. 2024 Dec 5;18:5729-5741. doi: 10.2147/DDDT.S471967. eCollection 2024.
6
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS AND PATIENTS TRANSITIONING FROM PEDIATRIC TO ADULT CARE.美国临床内分泌医师协会和美国内分泌学会成人生长激素缺乏症管理指南以及儿科向成人保健过渡患者的指南。
Endocr Pract. 2019 Nov;25(11):1191-1232. doi: 10.4158/GL-2019-0405.
7
Long-acting growth hormone in the management of GHD in France.长效生长激素在法国生长激素缺乏症治疗中的应用。
Arch Pediatr. 2024 Aug;31(6):357-364. doi: 10.1016/j.arcped.2024.03.009. Epub 2024 Jul 18.
8
Adherence to growth hormone therapy guidelines in a real-world French cohort of adult patients with growth hormone deficiency.真实世界中法国成年生长激素缺乏症患者队列中对生长激素治疗指南的依从性。
Ann Endocrinol (Paris). 2021 Feb;82(1):59-68. doi: 10.1016/j.ando.2020.11.007. Epub 2020 Dec 5.
9
Is safety of childhood growth hormone therapy related to dose? Data from a large observational study.儿童生长激素治疗的安全性与剂量有关吗？一项大型观察性研究的数据。
Eur J Endocrinol. 2016 May;174(5):681-91. doi: 10.1530/EJE-15-1017. Epub 2016 Feb 22.
10
Cardiovascular safety of growth hormone treatment in Noonan syndrome: real-world evidence.努南综合征患者生长激素治疗的心血管安全性：真实世界证据
Endocr Connect. 2022 Jan 31;11(1):e210549. doi: 10.1530/EC-21-0549.
本文引用的文献
1
Long-term risk of neoplastic events after childhood growth hormone treatment: a population-based cohort study in Sweden.儿童生长激素治疗后的长期肿瘤风险：瑞典基于人群的队列研究。
Front Endocrinol (Lausanne). 2024 Mar 5;15:1360139. doi: 10.3389/fendo.2024.1360139. eCollection 2024.
2
Cancer in growth hormone excess and growth hormone deficit.生长激素过多和过少相关的癌症。
Endocr Relat Cancer. 2023 Aug 14;30(10). doi: 10.1530/ERC-22-0402. Print 2023 Oct 1.
3
Strengthening evidence-based medicine with real-world evidence.用真实世界证据强化循证医学。
Lancet Healthy Longev. 2022 Oct;3(10):e641-e642. doi: 10.1016/S2666-7568(22)00214-8. Epub 2022 Sep 20.
4
Childhood growth hormone treatment and metabolic and cardiovascular risk in adults born small for gestational age after growth hormone cessation in the Netherlands: a 12-year follow-up study.荷兰小于胎龄儿成年后生长激素治疗停止后的儿童期生长激素治疗与代谢及心血管风险：一项12年随访研究
Lancet Child Adolesc Health. 2022 Nov;6(11):777-787. doi: 10.1016/S2352-4642(22)00240-1. Epub 2022 Sep 16.
5
Clinical Indications for Growth Hormone Therapy.生长激素治疗的临床适应证。
Adv Pediatr. 2022 Aug;69(1):203-217. doi: 10.1016/j.yapd.2022.03.005. Epub 2022 Jun 17.
6
Cardiovascular safety of growth hormone treatment in Noonan syndrome: real-world evidence.努南综合征患者生长激素治疗的心血管安全性：真实世界证据
Endocr Connect. 2022 Jan 31;11(1):e210549. doi: 10.1530/EC-21-0549.
7
Trial Emulation and Real-World Evidence.试验模拟与真实世界证据
JAMA Netw Open. 2021 Mar 1;4(3):e213845. doi: 10.1001/jamanetworkopen.2021.3845.
8
Long-Term Safety of Growth Hormone Treatment in Childhood: Two Large Observational Studies: NordiNet IOS and ANSWER.儿童时期生长激素治疗的长期安全性：两项大型观察性研究：NordiNet IOS 和 ANSWER。
J Clin Endocrinol Metab. 2021 May 13;106(6):1728-1741. doi: 10.1210/clinem/dgab080.
9
Association of Childhood Growth Hormone Treatment With Long-term Cardiovascular Morbidity.儿童时期生长激素治疗与长期心血管发病率的关联。
JAMA Pediatr. 2021 Feb 1;175(2):e205199. doi: 10.1001/jamapediatrics.2020.5199.
10
Circulating Insulin-like Growth Factor-I Concentrations and Risk of 30 Cancers: Prospective Analyses in UK Biobank.循环胰岛素样生长因子-I 浓度与 30 种癌症风险：英国生物库的前瞻性分析。
Cancer Res. 2020 Sep 15;80(18):4014-4021. doi: 10.1158/0008-5472.CAN-20-1281. Epub 2020 Jul 24.
Zotero 插件